Treatment of Chronic Functional Mitral Valve Regurgitation With a Percutaneous Annuloplasty System

详细信息    查看全文

• 作者：Georg Nickenig ; MD^a ; ^{georg.nickenig@ukb.uni-bonn.de" class="auth_mail" title="E-mail the corresponding author} ; Robert Schueler ; MD^a ; Antonio Dager ; MD^b ; Pedro Martinez Clark ; MD^b ; Alexandre Abizaid ; MD^c ; Tomasz Siminiak ; MD^d ; Pawel Buszman ; MD^e ; Marcin Demkow ; MD^f ; Adrian Ebner ; MD^g ; Federico M. Asch ; MD^h ; Christoph Hammerstingl ; MD^a
• 关键词：heart failure ; mitral regurgitation ; percutaneous annuloplasty
• 刊名：Journal of the American College of Cardiology
• 出版年：2016
• 出版时间：28 June 2016
• 年：2016
• 卷：67
• 期：25
• 页码：2927-2936
• 全文大小：1865 K

文摘

Current surgical and medical treatment options for functional mitral regurgitation (FMR) are limited and additional interventional approaches are required.

Objectives

This study sought to report the safety and performance data from the feasibility study with a novel direct annuloplasty system.

Methods

Seventy-one patients with moderate to severe FMR (mean 67.7 ± 11.3 years of age, left ventricular [LV] ejection fraction 34.0 ± 8.3%), on stable medical heart failure medication were prospectively enrolled.

Results

Device success rate was 70.4% (n = 50 of 71). No intraprocedural death occurred. In patients receiving implants, 4 patients (8.9%) experienced cardiac tamponade. Thirty-day (n = 45) and 6-month (n = 41) rates for all-cause mortality, stroke, and myocardial infarction were 4.4%, 4.4%, and 0.0% and 12.2%, 4.9%, and 0%, respectively. At 6 months, nonurgent mitral surgery was performed in 1 patient (2.4%) and nonurgent percutaneous repair in 7 patients (17.1%). Echocardiographic core analysis after 6 months showed mitral regurgitation reduction in 50% of treated patients by a mean of 1.3 grades. Concerning mitral valve (MV) annular geometry, we found significant reduction of anterior-posterior (–0.31 ± 0.4 cm) and septal-lateral dimensions (–0.21 ± 0.3 cm), a decreased MV-tenting area (–0.57 ± 1.1 cm²) and increase in MV coaptation length (0.13 ± 0.2 cm). Transthoracic echocardiography indicated reverse LV remodeling with reduction of LV end-diastolic diameter (–0.20 ± 0.4 mm) and volume (–22 ± 39 ml). Treatment was associated with significant improvement in 6-min walking distances (56.5 ± 92.0 m) and improvements in New York Heart Association functional class III/IV at 6 months from 53.3% to 23.3%.

Conclusions

Percutaneous direct annuloplasty is feasible and safe in high-risk FMR patients. This treatment initiates LV reverse remodeling, and provides clinical improvement during 6 months after treatment. (Mitralign Percutaneous Annuloplasty First in Man Study; NCT01852149).